Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29859278 | 1.00 | LPL (0.33) | LPLLIPGGAAKITKDR | |
| SCHEMBL29859422 | 0.81 | KDM4E (0.35) | KITKDRFLT3 | |
| SCHEMBL19989528 | 0.81 | KDM4E (0.35) | KITKDRFLT3 | |
| SCHEMBL22531558 | 0.79 | CHEK1 (0.34) | LPLLIPGKDRFLT3 | |
| SCHEMBL19989468 | 0.78 | KDR (0.37) | LPLLIPGGAAKITKDR | |
| SCHEMBL29859747 | 0.78 | KDR (0.37) | LPLLIPGGAAKITKDR | |
| SCHEMBL15995835 | 0.75 | CHEK1 (0.46) | LPLLIPGGAAKDRFLT3 | |
| SCHEMBL19989547 | 0.73 | GAA (0.43) | GAAKITKDRFLT3 | |
| SCHEMBL19989510 | 0.73 | PDPK1 (0.36) | GAAKITKDRFLT3 | |
| SCHEMBL29859433 | 0.73 | PDPK1 (0.36) | GAAKITKDRFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715608-B | Indazole compounds for use in tendon and/or ligament injuries | 诺华股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3515894-B1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3515894-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | Novartis AG (CH) | 2019-07-31 | — | — | EP | disclosed |
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2018-03-29 | — | — | US | disclosed |
| WO-2018055550-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | SLC10A2, MMP1, TNNI3 | LPL 2361/4885LIPG 2979/4885GAA 4269/4885 |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | MMP1, SLC10A2, TNNI3 | LPL 2473/4885LIPG 2875/4885GAA 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.